CBX 250
Alternative Names: CBX-250Latest Information Update: 16 Jun 2024
At a glance
- Originator Crossbow Therapeutics
- Developer Crossbow Therapeutics; M. D. Anderson Cancer Center
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myeloid leukaemia